Insights from Digital Pharma Leaders
Refine Search
Biotechnology
A biotech company called Seismic Therapeutic has launched with the aim of advancing machine learning for immunology drug development. 10 February 2022
Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
In this episode, we look at the potential impact of decentralized clinical trials, as increasing adoption of this kind of study forms part of a general movement towards greater use of innovative digital platforms for collecting and distributing clinical data. 10 February 2022
Pharmaceutical
Steve Kent, chairman at Pharmaspectra, a data business with a focus on medical affairs, provides an Expert View on the increasing impact of data in medicine. 27 January 2022
article
In another example of the growing popularity of the SPAC merger, digital medicine company Akili Interactive is to list on the Nasdaq in this way, with the deal expected to close in mid-2022. 26 January 2022
Biotechnology
US gene editing start-up Metagenomi has announced the completion of an up-sized and oversubscribed $175 million Series B financing. 26 January 2022
Biotechnology
2014-founded AI specialist InstaDeep has raised $100 million in a series B funding round, led by Alpha Intelligence Capital, together with CDIB. 25 January 2022
Biotechnology
California-based insitro, a machine learning-driven drug discovery and development company, has announced the expansion of its leadership team. 12 January 2022
Biotechnology
Licensing deals featured prominently in last week’s news, starting with Biogen last Tuesday saying it has exercised an option for rights to Ionis Pharmaceuticals’ BIIB115/ION306 for spinal muscular atrophy. Then US biotech giant Amgen inked an up to $1.9 billion agreement with machine learning start-up Generate Biomedicines to create new protein therapeutics. Also, US RNAi specialist Alnylam Pharmaceuticals signed a research collaboration with Swiss giant Novartis on therapies to restore liver function. And UK-based AstraZeneca signed a deal with Neurimmune for its rare disease candidate NI006 that could cost as much as $760 million. 9 January 2022
Biotechnology
Canada-headquartered artificial intelligence (AI) company Absci Corporation saw its shares leap more than 50% pre-market on Friday, on the back of new that it has entered into a research collaboration with Merck & Co for the US pharma giant to use Absci’s AI-powered Integrated Drug Creation Platform. 8 January 2022
Pharmaceutical
In what is an increasingly busy period for artificial intelligence (AI) research, privately-held AI company Iktos has agreed to work with South Korean biotech Astrogen to try to discover new small molecules for Parkinson's disease. 7 January 2022
Pharmaceutical
Building on a long and growing list of collaborations, artificial intelligence (AI) firm Exscientia has agreed terms for a new deal with Sanofi. 7 January 2022
Biotechnology
Biotech major Amgen and Generate Biomedicines have announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. 6 January 2022
Biotechnology
PhoreMost, a UK-based biopharma dedicated to developing drugs against intractable disease targets, has announced a collaboration to study oncology targets currently considered ‘undruggable’ with Polaris Quantum Biotech (POLARISqb), a North Carolina, USA-based quantum computing drug design company. 5 January 2022
Biotechnology
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episode, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI. 30 December 2021
Pharmaceutical
Research from British online pharmacy Chemist4U has revealed some insights on the current state of prescriptions in England, including the most prescribed medicines in the country. 22 December 2021
Biotechnology
UK-based artificial intelligence (AI) company BenevolentAI today said that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI's platform, to its drug development portfolio. 15 December 2021
Biotechnology
Odyssey Acquisition, a Euronext Amsterdam-listed special-purpose acquisition company (SPAC), and British biotech BenevolentAI, a clinical-stage AI drug discovery company, today announced that they have entered into a definitive agreement for a business combination. 7 December 2021
Pharmaceutical
Vicki Pearson, global solutions architect, life sciences at Schneider Electric, provides an Expert View on how firms can meet a growing demand while remaining affordable and accessible. 30 November 2021
Biotechnology
French pharma major Sanofi today announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programs in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments. 18 November 2021
Pharmaceutical
As the initial waves of the coronavirus pandemic hit in early 2020, pharma and biotech stocks saw major declines as investors digested the likely impact. 11 November 2021
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Biotechnology
Privately-held Boston-based biopharma FogPharma has announced a name change and unveiled a new AI-based platform. 11 November 2024
Pharmaceutical
A review has found that complexities and inefficiencies within the UK’s health data infrastructure are hindering the effective use of these resources that are critical for improving people’s health. 8 November 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Pharmaceutical
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pharmaceutical
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Biotechnology
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Pharmaceutical
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Biotechnology
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Biotechnology
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
Otsuka Pharmaceuticals says that its subsidiaries Otsuka Precision Health, Inc. (OPH) and Click Therapeutics (Click) have launched Rejoyn (developed as CT-152). 19 August 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
California’s ReviR Therapeutics has completed a $30 million series A financing round, bringing its total funding to $54 million. 29 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Biotechnology
AI-focused start-up Formation Bio has raised $372 million in a series D financing. 27 June 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze